Atara Biotherapeutics Inc.

5.13-0.4600-8.23%Vol 1.40M1Y Perf -61.53%
May 18th, 2022 16:00 DELAYED
BID4.88 ASK6.65
Open5.36 Previous Close5.59
Pre-Market- After-Market5.38
 - -  0.25 4.87%
Target Price
20.80 
Analyst Rating
Strong Buy 1.40
Potential %
305.46 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     45.03
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.91 
Earnings Rating
Strong Buy
Market Cap479.17M 
Earnings Date
5th May 2022
Alpha-0.01 Standard Deviation0.24
Beta1.92 

Today's Price Range

4.975.43

52W Range

4.8420.04

5 Year PE Ratio Range

-4.30-4.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
11.80%
1 Month
-27.68%
3 Months
-57.39%
6 Months
-68.65%
1 Year
-61.53%
3 Years
-76.70%
5 Years
-62.98%
10 Years
-

TickerPriceChg.Chg.%
ATRA5.13-0.4600-8.23
AAPL140.82-8.4200-5.64
GOOG2 248.02-86.0100-3.69
MSFT254.08-12.1200-4.55
XOM90.65-1.4600-1.59
WFC42.11-1.6000-3.66
JNJ175.50-3.3200-1.86
FB192.24-10.3800-5.12
GE75.20-1.2000-1.57
JPM120.09-2.0900-1.71
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.98-0.8711.22
Q04 2021-0.60-0.96-60.00
Q03 2021-0.92-0.902.17
Q02 2021-0.88-0.91-3.41
Q01 2021-0.93-0.867.53
Q04 2020-0.73-0.95-30.14
Q03 2020-1.10-0.9216.36
Q02 2020-1.21-1.145.79
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.917.14Positive
9/2022 QR-0.80-25.00Negative
12/2022 FY-3.453.09Positive
12/2023 FY-3.08-11.59Negative
Next Report Date-
Estimated EPS Next Report-0.98
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.40M
Shares Outstanding93.41K
Shares Float91.03M
Trades Count12.36K
Dollar Volume7.20M
Avg. Volume1.11M
Avg. Weekly Volume1.26M
Avg. Monthly Volume988.81K
Avg. Quarterly Volume1.07M

Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock closed at 5.59 per share at the end of the most recent trading day (a 5.47% change compared to the prior day closing price) with a volume of 1.30M shares and market capitalization of 479.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Atara Biotherapeutics Inc. CEO is Pascal Touchon.

The one-year performance of Atara Biotherapeutics Inc. stock is -61.53%, while year-to-date (YTD) performance is -64.53%. ATRA stock has a five-year performance of -62.98%. Its 52-week range is between 4.84 and 20.04, which gives ATRA stock a 52-week price range ratio of 1.91%

Atara Biotherapeutics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 2.28, a price-to-sale (PS) ratio of 20.54, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -77.98%, a ROC of -107.11% and a ROE of -116.42%. The company’s profit margin is -%, its EBITDA margin is -1 417.80%, and its revenue ttm is $24.10 Million , which makes it $0.26 revenue per share.

Of the last four earnings reports from Atara Biotherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.98 for the next earnings report. Atara Biotherapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Atara Biotherapeutics Inc. is Strong Buy (1.4), with a target price of $20.8, which is +305.46% compared to the current price. The earnings rating for Atara Biotherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atara Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atara Biotherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.73, ATR14 : 0.59, CCI20 : -94.73, Chaikin Money Flow : -0.11, MACD : -0.85, Money Flow Index : 33.74, ROC : -12.11, RSI : 34.46, STOCH (14,3) : 30.24, STOCH RSI : 1.00, UO : 35.52, Williams %R : -69.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atara Biotherapeutics Inc. in the last 12-months were: Amar Murugan (Sold 6 781 shares of value $87 823 ), Jakob Dupont (Option Excercise at a value of $143 700), Jakob Dupont (Sold 21 572 shares of value $328 599 ), Joseph Newell (Option Excercise at a value of $170 100), Joseph Newell (Sold 29 874 shares of value $491 088 ), Matthew K. Fust (Sold 13 354 shares of value $260 403 ), Pascal Touchon (Sold 39 647 shares of value $565 536 ), Utpal Koppikar (Sold 19 313 shares of value $262 429 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.00
Strong Buy
1.00

Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.

CEO: Pascal Touchon

Telephone: +1 650 278-8930

Address: 611 Gateway Boulevard, South San Francisco 94080, CA, US

Number of employees: 429

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

75%25%

Bearish Bullish

72%28%

Bearish Bullish

67%33%

TipRanks News for ATRA

Fri, 06 May 2022 01:35 GMT Analysts Top Healthcare Picks: Atara Biotherapeutics (ATRA), Cassava Sciences (SAVA)

- TipRanks. All rights reserved.

Fri, 14 Jan 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: Prophase Labs (PRPH), Atara Biotherapeutics (ATRA) and FibroGen (FGEN)

- TipRanks. All rights reserved.

Wed, 12 Jan 2022 21:45 GMT Atara Biotherapeutics (ATRA) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits